COSTA MESA, Calif.--(BUSINESS WIRE)--Aug. 17, 2006--Valeant Pharmaceuticals International (NYSE:VRX) today announced the availability of Cesamet (CII) (nabilone) oral capsules in U.S. pharmacies nationwide. Valeant received approval for Cesamet, a synthetic cannabinoid, from the Food and Drug Administration (FDA) on May 15, 2006 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatments. The Company also announced the initiation of a post-marketing clinical trial in emesis to further explore the patient benefit in using Cesamet to control chemotherapy-induced nausea and vomiting (CINV) and its potential impact on quality of life.
